Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BSG005 in Healthy Subjects
NCT04921254Phase 1Unknown
- Sponsor
- Biosergen
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in invasive fungal infection (IFI) comparing BSG005 with Placebo (2 arms). Primary endpoint: Adverse Events recorded during and after BSG005 infusion. Status: unknown.
02
Drugs
BSG005
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT04921254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921254.